As is typical of an industry tied so closely to legislation and the markets, the state of retail pharmacy is typically one in flux. With 2016 in the rearview mirror and both 2017 and a new presidential administration ahead, what are the biggest changes facing the industry?
Forbes is reporting that the Food and Drug Administration’s approval of 22 new drugs in 2016 (down from 51 in 2015) could have big implications for the future of innovation in the pharmaceutical space. The report notes that research spending is growing, but there are practical difficulties to translate innovation into products as R&D returns decline — and the report suggests overcoming that difficulty could mean rethinking a lot. (Forbes)
Novo Nordisk accused of issuing marketing materials asking patients and doctors to switch from Sanofi’s Lantus and Toujeo drugs to Tresiba, because the Sanofi drugs will be “blocked” by CVS Caremark in January.